Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | UGCG | Q16739 | 1/20 | 0.47 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.45 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031149 | 0.84 | CHRNA7 (0.54) | MEN1KMT2AHSD11B1CHRNA7HTR3A | |
| SCHEMBL4032137 | 0.82 | HSD11B1 (0.54) | HSD11B1CHRNA7MGLLHTR3A | |
| SCHEMBL4028418 | 0.80 | CHRNA7 (0.52) | HPGDKMT2AHSD11B1CHRNA7MGLL | |
| SCHEMBL4031884 | 0.80 | CHRNA7 (0.52) | CHRNA7MGLLHTR3A | |
| SCHEMBL4028569 | 0.80 | CHRNA7 (0.62) | HPGDHSD11B1CHRNA7MGLLHTR3A | |
| SCHEMBL4030570 | 0.80 | CHRNA7 (0.60) | CHRNA7HTR3A | |
| SCHEMBL5914732 | 0.79 | CHRNA7 (0.69) | CHRNA7HTR3A | |
| SCHEMBL4705060 | 0.78 | CHRNA7 (0.48) | GAACHRNA7HTR3A | |
| SCHEMBL4700437 | 0.78 | CHRNA7 (0.55) | MEN1HPGDTSHRKMT2AHSD11B1 | |
| SCHEMBL373468 | 0.77 | CHRNA7 (0.55) | MEN1HPGDTSHRKMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | claimed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | CHRNA7, CHRNB1, CHRNA1 | MEN1 2886/4885HPGD 1700/4885TSHR 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.